News

Cytovance Biologics continues to work on the expansion of a manufacturing operations and GMP warehousing facility in Oklahoma.

Shimadzu's new Solution Center features additional research space.

Mylan Pharmaceuticals launches Hertraz, the world's first trastuzumab biosimilar in India.

Aesica appoints Ian Muir to the newly created position of commercial managing director.

Sartorius appoints Michael Melingo to head marketing, sales, and services of the Lab Products & Services Division.

FDA plans to issue a number of new guidances in 2014 that will address drug development and manufacturing practices.

NIH, 10 biopharmaceutical companies, and several nonprofit organizations form a partnership to develop new treatments earlier for Alzheimer's, type 2 diabetes, and autoimmune disorders.

Thermo Fisher Scientific outlines new business segments with acquisition of Life Technologies.

Edison and DSP partner to develop drugs targeting cellular energy metabolism.

EMD Millipore's expands its Emprove raw materials portfolio to include 400 products.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

EMA's guidance focuses on the use of pharmacogenomics to improve drug safety monitoring.

NCI launches trial to assess the utility of genetic sequencing to improve patient outcomes.

Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.

FDA adds Ranbaxy's Toansa, India facility to existing consent decree, prohibiting distribution of APIs from that location

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

Shire appoints Susan Kilsby as its New Chairman.

Teva announced an agreement to acquire NuPathe and its migraine treatment patch.

The Natural Product Center of Excellence seeks to identify novel active compounds for new antibiotics.

J&J's diagnostics business goes to global asset manager, The Carlyle Group.

The Stevens Institute of Technology will open a new biotechnology laboratory in January 2014.

Combined technologies from Agilent Technologies and Picometrics Technologies are designed for large–molecule analysis.

Novasep selects Thierry van Nieuwenhove as new president of the synthesis business unit.

Lonza signs an agreement with Index Ventures for the development and manufacture of biologics for portfolio companies.

USP opens expanded Shanghai facility to enhance quality standards for medicines and food ingredients.

CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.

A packaging defect has led to Merck voluntarily recalling all lots of Liptruzet tablets in the United States.